# MOUNTAINEER (NCT03043313)

> Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

No report yet. It can be ordered.

- Drugs tested: tucatinib plus trastuzumab; tucatinib
- Indication: chemotherapy-refractory HER2-positive RAS wild-type metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03043313
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Seagen Inc.
- Conditions: Metastatic Colorectal Adenocarcinoma
- Interventions: Trastuzumab; Tucatinib
- Enrollment: 117
- Primary outcome: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B

## Indexed commentary on MOUNTAINEER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 70
- X threads: 62
- YouTube: 52
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=mountaineer-nct03043313

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03043313", "email": "<work email>"}; the inbox owner confirms by the emailed link.